Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02547818 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
A Phase 3 study, sponsored by AZTherapies.
- Completed
- Registry status
- Phase 3
- Development phase
- 620
- Enrollment target
NCT02547818: Completed Phase 3 study, sponsored by AZTherapies.
NCT02547818 is a Phase 3 study that has completed, run by AZTherapies. The registered enrollment target is 620 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02547818, a Phase 3 study, has completed, sponsored by AZTherapies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 620 participants
- Enrollment target
Study Summary
This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early stage Alzheimer's disease (AD).
Primary Outcome
The combination active treatment group will be compared to each of the single component groups, including the placebo group, the mean change from Baseline to Week 72 will be quantified.
Interventions
- DRUG ALZT-OP1a
- DRUG ALZT-OP1b
- OTHER Placebo ALZT-OP1a
- OTHER Placebo ALZT-OP1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 620 participants |
| Start Date | 2015-09-15 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 3 |
What the finished NCT02547818 record still lists
NCT02547818 is an interventional study that assigns participants to a tested intervention. The registered 620 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% lower).
The record links to 0 conditions, and to 4 interventions - of which ALZT-OP1a is the first listed.
NCT02547818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02547818 about?
NCT02547818 is a clinical study titled "Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease". This is a global Phase III, randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subje...
What is the current status of trial NCT02547818?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 620 participants. The study started on 2015-09-15. Estimated completion is 2020-11-18.
What interventions are being tested in trial NCT02547818?
The interventions under investigation include: ALZT-OP1a (DRUG), ALZT-OP1b (DRUG), Placebo ALZT-OP1a (OTHER), Placebo ALZT-OP1b (OTHER).
Who is sponsoring clinical trial NCT02547818?
This trial is sponsored by AZTherapies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02547818's enrollment target sits among peer trials
620 589th of 2000 higher than 1,410 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02282969 · 620 participants
PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing
- NCT02838836 · 620 participants
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- NCT05538910 · 620 participants · NA
Defining Neurobiological Links Between Substance Use and Mental Illness
- NCT05822466 · 620 participants · NA
Virtual Tai ji Quan Exercise to Prevent Falls in Older Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI